CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Investing Cash Flow
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Investing Cash Flow of -$379.75 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-27 was $28.10M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-28 was -$407.85M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-27 was -$92.81M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-27 was -$33.70M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$209.32M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$245.09M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$563.15M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$607.92M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-27 | $28.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$379.75M 10-Q · filed 2026-08-05 | -$472.56M derived: sum of 3 quarters · filed 2026-08-05 | -$506.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | -$407.85M 10-Q · filed 2026-05-07 | -$500.65M derived: sum of 2 quarters · filed 2026-05-07 | -$534.35M derived: sum of 3 quarters · filed 2026-05-07 | -$571.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | -$92.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$126.50M derived: sum of 2 quarters · filed 2026-02-18 | -$163.84M derived: sum of 3 quarters · filed 2026-08-05 | -$209.32M 10-K · filed 2026-02-18 |
| 2025-09-27 | -$33.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$71.03M derived: sum of 2 quarters · filed 2026-08-05 | -$116.51M 10-Q · filed 2025-11-05 | -$192.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | -$37.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$82.82M 10-Q · filed 2026-08-05 | -$158.92M derived: sum of 3 quarters · filed 2026-08-05 | -$180.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | -$45.48M 10-Q · filed 2026-05-07 | -$121.58M derived: sum of 2 quarters · filed 2026-05-07 | -$142.91M derived: sum of 3 quarters · filed 2026-05-07 | -$204.77M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | -$76.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$97.43M derived: sum of 2 quarters · filed 2026-02-18 | -$159.29M derived: sum of 3 quarters · filed 2026-02-18 | -$245.09M 10-K · filed 2026-02-18 |
| 2024-09-28 | -$21.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$83.19M derived: sum of 2 quarters · filed 2025-11-05 | -$168.98M 10-Q · filed 2025-11-05 | -$407.35M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | -$61.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$147.66M 10-Q · filed 2025-08-06 | -$386.03M derived: sum of 3 quarters · filed 2026-02-18 | -$465.59M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | -$85.79M 10-Q · filed 2025-05-07 | -$324.16M derived: sum of 2 quarters · filed 2026-02-18 | -$403.72M derived: sum of 3 quarters · filed 2026-02-18 | -$480.33M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | -$238.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$317.93M derived: sum of 2 quarters · filed 2026-02-18 | -$394.54M derived: sum of 3 quarters · filed 2026-02-18 | -$563.15M 10-K · filed 2026-02-18 |
| 2023-09-30 | -$79.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$156.17M derived: sum of 2 quarters · filed 2024-11-06 | -$324.78M 10-Q · filed 2024-11-06 | -$280.40M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | -$76.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$245.23M 10-Q · filed 2024-08-07 | -$200.84M derived: sum of 3 quarters · filed 2025-02-19 | -$293.03M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-04-01 | -$168.62M 10-Q · filed 2024-05-09 | -$124.23M derived: sum of 2 quarters · filed 2025-02-19 | -$216.42M derived: sum of 3 quarters · filed 2025-02-19 | -$678.53M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $44.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$47.80M derived: sum of 2 quarters · filed 2025-02-19 | -$509.92M derived: sum of 3 quarters · filed 2025-02-19 | -$607.92M 10-K · filed 2025-02-19 |
| 2022-09-24 | -$92.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$554.30M derived: sum of 2 quarters · filed 2023-11-08 | -$652.30M 10-Q · filed 2023-11-08 | -$643.00M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-25 | -$462.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$560.12M 10-Q · filed 2023-08-09 | -$550.81M derived: sum of 3 quarters · filed 2024-02-14 | -$905.86M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-26 | -$98.00M 10-Q · filed 2023-05-11 | -$88.70M derived: sum of 2 quarters · filed 2024-02-14 | -$443.75M derived: sum of 3 quarters · filed 2024-02-14 | -$1.40B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-25 | $9.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$345.74M derived: sum of 2 quarters · filed 2024-02-14 | -$1.30B derived: sum of 3 quarters · filed 2024-02-14 | -$1.44B 10-K · filed 2024-02-14 |
| 2021-09-25 | -$355.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$1.31B derived: sum of 2 quarters · filed 2022-11-02 | -$1.45B 10-Q · filed 2022-11-02 | -$1.54B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | -$954.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$1.09B 10-Q · filed 2022-08-03 | -$1.18B derived: sum of 3 quarters · filed 2023-02-22 | -$1.25B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | -$138.00M 10-Q · filed 2022-05-04 | -$226.42M derived: sum of 2 quarters · filed 2023-02-22 | -$297.23M derived: sum of 3 quarters · filed 2023-02-22 | -$325.86M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | -$88.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$159.23M derived: sum of 2 quarters · filed 2023-02-22 | -$187.86M derived: sum of 3 quarters · filed 2023-02-22 | -$601.54M 10-K · filed 2023-02-22 |
| 2020-09-26 | -$70.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$99.44M derived: sum of 2 quarters · filed 2021-11-03 | -$513.12M 10-Q · filed 2021-11-03 | -$583.99M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | -$28.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$442.31M 10-Q · filed 2021-08-04 | -$513.18M derived: sum of 3 quarters · filed 2022-02-16 | -$574.58M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | -$413.69M 10-Q · filed 2021-05-04 | -$484.56M derived: sum of 2 quarters · filed 2022-02-16 | -$545.95M derived: sum of 3 quarters · filed 2022-02-16 | -$1.07B derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | -$70.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | -$132.26M derived: sum of 2 quarters · filed 2022-02-16 | -$660.69M derived: sum of 3 quarters · filed 2022-02-16 | -$681.50M 10-K · filed 2022-02-16 |
| 2019-09-28 | -$61.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$589.82M derived: sum of 2 quarters · filed 2020-10-29 | -$610.63M 10-Q · filed 2020-10-29 | -$681.59M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-29 | -$528.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$549.24M 10-Q · filed 2020-08-05 | -$620.19M derived: sum of 3 quarters · filed 2021-02-17 | -$653.21M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-30 | -$20.81M 10-Q · filed 2020-05-07 | -$91.77M derived: sum of 2 quarters · filed 2021-02-17 | -$124.78M derived: sum of 3 quarters · filed 2021-02-17 | -$951.15M derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-29 | -$70.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$103.97M derived: sum of 2 quarters · filed 2021-02-17 | -$930.34M derived: sum of 3 quarters · filed 2021-02-17 | -$955.00M 10-K · filed 2021-02-17 |
| 2018-09-29 | -$33.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$859.38M derived: sum of 2 quarters · filed 2019-11-06 | -$884.05M 10-Q · filed 2019-11-06 | -$916.87M derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-06-30 | -$826.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$851.04M 10-Q · filed 2019-07-31 | -$883.86M derived: sum of 3 quarters · filed 2020-02-11 | |
| 2018-03-31 | -$24.66M 10-Q · filed 2019-05-07 | -$57.49M derived: sum of 2 quarters · filed 2020-02-11 | ||
| 2017-12-30 | -$32.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | -$72.59M 10-K · filed 2020-02-11 | ||
| 2017-09-30 | -$39.76M 10-Q · filed 2018-11-07 | |||
| 2016-12-31 | -$692.67M 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |